熊去氧胆酸治疗无症状原发性硬化性胆管炎。

Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid.

作者信息

Hayashi H, Higuchi T, Ichimiya H, Hishida N, Sakamoto N

机构信息

Third Department of Medicine, Nagoya University School of Medicine, Japan.

出版信息

Gastroenterology. 1990 Aug;99(2):533-5. doi: 10.1016/0016-5085(90)91038-8.

DOI:10.1016/0016-5085(90)91038-8

PMID:2365199

Abstract

Ursodeoxycholic acid treatment (600 mg/day) was evaluated in a patient with asymptomatic primary sclerosing cholangitis. Serum levels of biliary enzymes decreased to normal ranges within 1 month's treatment and remained normal for 26 months. Serum chenodeoxycholic acid had been replaced by ursodeoxycholic acid, and hepatic copper metabolism, assessed by x-ray probe analysis, improved during the treatment. However, neither biliary tract sclerosis nor portal tract pathology changed with the treatment. These observations suggest that ursodeoxycholic acid protects the liver in primary sclerosing cholangitis by improving the metabolism of bile acid and copper.

摘要

对一名无症状原发性硬化性胆管炎患者进行了熊去氧胆酸治疗（600毫克/天）评估。治疗1个月内，胆汁酶血清水平降至正常范围，并在26个月内保持正常。鹅去氧胆酸血清水平已被熊去氧胆酸取代，通过X射线探针分析评估的肝脏铜代谢在治疗期间有所改善。然而，治疗后胆道硬化和门管区病理均未改变。这些观察结果表明，熊去氧胆酸通过改善胆汁酸和铜的代谢来保护原发性硬化性胆管炎患者的肝脏。